Since the half-life of HSA is about 15–21 days, it cannot be immediately utilized by the human body, which means that exogenous HSA cannot correct hypoproteinemia immediately in cancer patients (Sikuler et al., 2000; Talasaz et al., 2012). Here, ALB is linked to cancer.